

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: S. Kumar Examiner #: 64594 Date: 1/24/03
 Art Unit: 1621 Phone Number 30 8 4519 Serial Number: 101 031,486
 Mail Box and Bldg/Room Location: (M) 7200 7E12 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. MEY

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.



Title of Invention: Charybdis bis ammonium salt precursors and their use as prodrugs

Inventors (please provide full names): Henri Vial et al

Earliest Priority Filing Date: 7/21/1999

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 E07 - 703-308-4498
jan.delaval@uspto.gov



See claim 1 for various definitions.

Also see claims 8, 10, 12, 14, & 15.

Claim 25



STAFF USE ONLY


Searcher: Car
 Searcher Phone #: 4498
 Searcher Location: _____
 Date Searcher Picked Up: 2/3/03
 Date Completed: 2/3/03
 Searcher Prep & Review Time: _____
 Clerical Prep Time: 28
 Online Time: + 60

| Type of Search | Vendors and cost where applicable |
|-----------------|-----------------------------------|
| NA Sequence (#) | STN |
| AA Sequence (#) | Dialog |
| Structure (#) | Questel/Orbit |
| Bibliographic | Dr. Link |
| Litigation | Lexis/Nexis |
| Fulltext | Sequence Systems |
| Patent Family | WWW/Internet |
| Other | Other (specify) |

BioTech-Chem Library

Search Results

Feedback Form (Optional)



Scientific & Technical Information Center

The search results generated for your recent request are attached. If you have any questions or comments (compliments or complaints) about the scope or the results of the search, please contact *the BioTech-Chem searcher* who conducted the search *or contact*:

Mary Hale, Supervisor, 308-4258
CM-1 Room 1E01

Voluntary Results Feedback Form

➤ *I am an examiner in Workgroup:* (Example: 1610)

➤ *Relevant prior art found, search results used as follows:*

- 102 rejection
- 103 rejection
- Cited as being of interest.
- Helped examiner better understand the invention.
- Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- Foreign Patent(s)
- Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ *Relevant prior art not found:*

- Results verified the lack of relevant prior art (helped determine patentability).
- Search results were not useful in determining patentability or understanding the invention.

Other Comments:

Drop off completed forms at the **Circulation Desk CM-1**, or send to Mary Hale, **CM1-1E01 or e-mail** mary.hale@uspto.gov.

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:57:54 ON 03 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Feb 2003 VOL 138 ISS 6
FILE LAST UPDATED: 2 Feb 2003 (20030202/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 150 all hitstr

L50 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:63952 HCAPLUS
DN 134:131521
TI Preparation of neutral prodrugs of **bisquaternaryammonium parasiticides**
IN Vial, Henri; Calas, Michele; Ancelin, Marie-Laure; Bourguignon, Jean-Jacques; Vidal, Valerie; Rubi, Eric
PA Centre National de la Recherche Scientifique (C.N.R.S.), Fr.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA French
IC ICM C07C211-09
ICS C07C327-30; C07C323-27; C07C323-59; C07D277-22; C07D277-24; C07D277-30; C07D295-14; A61K031-14; A61K031-145; A61K031-425; A61P033-06; C07D327-06
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|--------------|
| ----- | ---- | ----- | ----- | ----- |
| PI WO 2001005742 | A1 | 20010125 | WO 2000-FR2122 | 20000721 <-- |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| FR 2796642 | A1 | 20010126 | FR 1999-9471 | 19990721 <-- |
| FR 2796642 | B1 | 20011019 | | |
| EP 1196371 | A1 | 20020417 | EP 2000-958598 | 20000721 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |

BR 2000012601 A 20020521 BR 2000-12601 20000721 <--
 PRAI FR 1999-9471 A 19990721 <--
 WO 2000-FR2122 W 20000721 <--

OS MARPAT 134:131521

AB Title compds., e.g., $Z[N(CHO)CR2:CR3SRa]2$ [I; Ra = R, SR, COR; R = (un)substituted alkyl, -Ph, heterocyclylmethyl, etc.; R2 = H, alkyl, alkoxy carbonylmethyl; R3 = H, alk(en)yl, etc.; RR3, R2R3 = atoms to complete a ring; Z = (heteroatom- or arylene-interrupted)(satd.) alkylene] were prepd. Thus, 5-(2-hydroxymethyl)-4-methylthiazole was condensed with Br(CH2)12Br to give the bisthiazolium dibromide (drug) which was biscondensed with PrSSO3Na (prepn. given) to give I [Ra = SPr, R2 = Me, R3 = CH2CH2OH, Z = (CH2)12] (prodrug). Data for biol. activity of title compds. were given.

ST prodrug bisquaternaryammonium parasiticide;
 antimalarial bisquaternaryammonium prodrug

IT Antimalarials
 Parasiticides
 (prepn. of neutral prodrugs of bisquaternaryammonium
 parasiticides)

IT 321915-72-4P 321915-73-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of neutral prodrugs of bisquaternaryammonium
 parasiticides)

IT 321915-74-6P 321915-75-7P 321915-76-8P
 321915-77-9P 321915-78-0P 321915-79-1P
 321915-80-4P 321915-81-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of neutral prodrugs of bisquaternaryammonium
 parasiticides)

IT 321915-50-8P 321915-51-9P 321915-52-0P
 321915-53-1P 321915-54-2P 321915-55-3P
 321915-56-4P 321915-57-5P 321915-58-6P
 321915-59-7P 321915-60-0P 321915-61-1P
 321915-62-2P 321915-63-3P 321915-64-4P
 321915-65-5P 321915-66-6P 321915-67-7P
 321915-68-8P 321915-69-9P 321915-70-2P
 321915-71-3P 321915-82-6P 321915-83-7P
 321915-84-8P 321915-85-9P 321915-92-8P
 321915-93-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of neutral prodrugs of bisquaternaryammonium
 parasiticides)

IT 98-88-4, Benzoyl chloride 100-07-2, p-Methoxybenzoyl chloride
 100-39-0, Benzyl bromide 106-94-5, Propyl bromide 108-29-2,
 .gamma.-Valerolactone 109-89-7, Diethylamine, reactions 110-91-8,
 Morpholine, reactions 137-00-8, 4-Methyl-5-(2-hydroxyethyl)thiazole
 141-97-9, Ethyl acetoacetate 629-09-4, 1,6-Diodohexane 693-95-8,
 4-Methylthiazole 1642-81-5, 4-Chloromethylbenzoic acid 3003-84-7,
 Tetrahydrofurfuryl chloride 3344-70-5, 1,12-Dibromododecane 5259-98-3,
 5-Chloro-1-pentanol 7377-26-6, Benzoic acid, 4-chlorocarbonyl, methyl
 ester 7735-42-4, Hexadecane-1,16-diol
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of neutral prodrugs of bisquaternaryammonium
 parasiticides)

IT 2751-70-4P 6313-36-6P 6363-00-4P 24772-65-4P, 1,12-Diiodododecane
 24772-67-6P, 1,16-Diiodohexadecane 51023-75-7P 62642-59-5P
 62642-62-0P 77339-73-2P 89585-19-3P 98316-89-3P,
 4-Methyl-5-(2'-methoxyethyl)thiazole 106261-54-5P 123742-32-5P
321915-86-0P 321915-87-1P 321915-88-2P **321915-89-3P**
 321915-90-6P 321915-91-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of neutral prodrugs of **bisquaternaryammonium**
parasiticides)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Hikoichi, H; US 3278537 A 1966
- (2) Libman, D; JOURNAL OF THE CHEMICAL SOCIETY 1952, P2305 HCPLUS
- (3) Lopez-Calahorra, F; HETEROCYCLES 1994, V37(3), P1570
- (4) Marti; TETRAHEDRON LETT 1993, V34(3), P521 HCPLUS
- (5) Mitchell, R; CHEMICAL ABSTRACTS 1961, V55(12)
- (6) Mitchell, R; J PHARMACOL EXPTL THERAP 1961, V131, P334 HCPLUS
- (7) Virbac Sa; FR 2751967 A 1998 HCPLUS
- (8) Zirkle, C; US 3131220 A 1964 HCPLUS


IT **321915-72-4P** **321915-73-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of neutral prodrugs of **bisquaternaryammonium**
parasiticides)

RN 321915-72-4 HCPLUS


CN Thiazolium, 3,3'-(1,12-dodecanediyl)bis[5-(2-hydroxyethyl)-4-methyl-,
 dibromide (9CI) (CA INDEX NAME)



●2 Br⁻

RN 321915-73-5 HCPLUS

CN Thiazolium, 3,3'-(1,12-dodecanediyl)bis[5-(2-methoxyethyl)-4-methyl-,
 dibromide (9CI) (CA INDEX NAME)



●2 Br⁻


IT 321915-74-6P 321915-75-7P 321915-76-8P
 321915-77-9P 321915-78-0P 321915-79-1P
 321915-80-4P 321915-81-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of neutral prodrugs of **bisquaternaryammonium parasiticides**)

RN 321915-74-6 HCPLUS


CN Thiazolium, 3,3'-(1,12-dodecanediyl)bis[4-methyl-, diiodide (9CI) (CA INDEX NAME)



2 I⁻

RN 321915-75-7 HCPLUS

CN Thiazolium, 3,3'-(1,16-hexadecanediyl)bis[5-(2-methoxyethyl)-4-methyl-, diiodide (9CI) (CA INDEX NAME)




●2 I⁻


RN 321915-76-8 HCPLUS

CN Thiazolium, 5,5'-[1,6-hexanediylbis(oxy-2,1-ethanediyl)]bis[3,4-dimethyl-, diiodide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●2 I-


RN 321915-77-9 HCAPLUS

CN Thiazolium, 5,5'-[1,6-hexanediylbis(oxy-2,1-ethanediyl)]bis[4-methyl-3-(phenylmethyl)-, dibromide (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



2 Br-


RN 321915-78-0 HCAPLUS

CN Thiazolium, 5,5'-(1,12-dodecanediyl)bis[4-(2-ethoxy-2-oxoethyl)-3-methyl-, diiodide (9CI) (CA INDEX NAME)

●2 I⁻


RN 321915-79-1 HCAPLUS

CN Thiazolium, 5,5'-(1,12-dodecanediyl)bis[4-(2-ethoxy-2-oxoethyl)-3-(phenylmethyl)-, dibromide (9CI) (CA INDEX NAME)


●2 Br⁻

RN 321915-80-4 HCAPLUS

CN Thiazolium, 4,4'-(1,12-dodecanediyl)bis[3-methyl-, diiodide (9CI) (CA INDEX NAME)

●2 I⁻


RN 321915-81-5 HCAPLUS
 CN Thiazolium, 4,4'-(1,12-dodecanediyl)bis[3-(phenylmethyl)-, dibromide (9CI)
 (CA INDEX NAME)

●2 Br⁻


IT 321915-50-8P 321915-51-9P 321915-52-0P
 321915-53-1P 321915-54-2P 321915-55-3P
 321915-56-4P 321915-57-5P 321915-58-6P
 321915-59-7P 321915-60-0P 321915-61-1P
 321915-62-2P 321915-63-3P 321915-64-4P
 321915-65-5P 321915-66-6P 321915-67-7P
 321915-68-8P 321915-69-9P 321915-70-2P
 321915-71-3P 321915-82-6P 321915-83-7P
 321915-84-8P 321915-85-9P 321915-92-8P
 321915-93-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of neutral prodrugs of **bisquaternaryammonium parasiticides**)


RN 321915-50-8 HCAPLUS
 CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-hydroxy-1-methyl-2-[(tetrahydro-2-furanyl)methyl]dithio]-1-butenyl]- (9CI) (CA INDEX NAME)




RN 321915-51-9 HCAPLUS
 CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-hydroxy-1-methyl-2-(propyldithio)-1-butenyl]- (9CI) (CA INDEX NAME)




RN 321915-52-0 HCAPLUS
 CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-hydroxy-1-methyl-2-(phenylmethyl)dithio]-1-butenyl]- (9CI) (CA INDEX NAME)




RN 321915-53-1 HCAPLUS
 CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-hydroxy-2-[(2-hydroxyethyl)dithio]-1-methyl-1-butenyl]- (9CI) (CA INDEX NAME)




RN 321915-54-2 HCAPLUS
 CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-methoxy-1-methyl-2-(propyldithio)-1-butenyl]- (9CI) (CA INDEX NAME)




RN 321915-55-3 HCAPLUS
 CN Formamide, N,N'-1,12-dodecanediylbis[N-[1-methyl-2-(propyldithio)ethenyl]- (9CI) (CA INDEX NAME)



RN 321915-56-4 HCAPLUS
 CN Ethanethioic acid, S,S'-[1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]]] ester (9CI) (CA INDEX NAME)




RN 321915-57-5 HCAPLUS
 CN Propanethioic acid, 2,2-dimethyl-, S,S'-[1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]]] ester (9CI) (CA INDEX NAME)





RN 321915-58-6 HCAPLUS

CN Benzenecarbothioic acid, S,S'-(1,12-dodecanediyl)bis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester (9CI) (CA INDEX NAME)



RN 321915-59-7 HCAPLUS



CN Benzenecarbothioic acid, 4-methoxy-, S,S'-[1,12-dodecanediyl]bis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester (9CI) (CA INDEX NAME)



RN 321915-60-0 HCAPLUS

CN Benzenecarbothioic acid, 4-[2-(4-morpholinyl)ethoxy]-, S,S'-(1,12-dodecanediyl)bis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B

— CH₂—OMe

RN 321915-61-1 HCAPLUS

CN Benzenecarbothioic acid, 4-[(diethylamino)methyl]-, S,S'-[1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]]] ester, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 321915-62-2 HCAPLUS

CN Benzenecarbothioic acid, 4-(4-morpholinylmethyl)-, S,S'-[1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]]] ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B




RN 321915-63-3 HCAPLUS

CN Benzoic acid, 4,4'-[5,18-diformyl-3,20-bis(2-methoxyethyl)-4,19-dimethyl-1,22-dioxo-2,21-dithia-5,18-diazadocosa-3,19-diene-1,22-diyl]bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 321915-64-4 HCAPLUS

CN Benzenecarbothioic acid, S,S'-[1,16-hexadecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]]] ester (9CI) (CA INDEX NAME)



RN 321915-65-5 HCAPLUS


CN Formamide, N,N'-1,12-dodecanediylbis[N-[1-(2-oxo-1,3-oxathian-4-ylidene)ethyl]- (9CI) (CA INDEX NAME)



RN 321915-66-6 HCPLUS

CN Benzenecarbothioic acid, 4-methoxy-, S,S'-[1,6-hexanediylbis[oxy[1-[1-(formylmethylamino)ethylidene]-3,1-propanediyl]]] ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 321915-67-7 HCPLUS

CN Benzenecarbothioic acid, 4-methoxy-, S,S'-[1,6-hexanediylbis[oxy[1-[1-[formyl(phenylmethyl)amino]ethylidene]-3,1-propanediyl]]] ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 321915-68-8 HCAPLUS

CN 3,17-Eicosadienedioic acid, 4,17-bis(benzoylthio)-3,18-bis(formylmethylamino)-, diethyl ester (9CI) (CA INDEX NAME)




RN 321915-69-9 HCAPLUS

CN 3,17-Eicosadienedioic acid, 4,17-bis(benzoylthio)-3,18-bis[formyl(phenylmethyl)amino]-, diethyl ester (9CI) (CA INDEX NAME)




RN 321915-70-2 HCAPLUS

CN Benzenecarbothioic acid, S,S'-[2,15-bis(formylmethylamino)-1,15-hexadecadiene-1,16-diyl] ester (9CI) (CA INDEX NAME)




RN 321915-71-3 HCAPLUS

CN Benzenecarbothioic acid, S,S'-[2,15-bis[formyl(phenylmethyl)amino]-1,15-hexadecadiene-1,16-diyl] ester (9CI) (CA INDEX NAME)



RN 321915-82-6 HCAPLUS


CN 1,16-Hexadecanediamine, N,N'-bis(5-chloropentyl)-N,N'-dimethyl-,
hydrochloride (9CI) (CA INDEX NAME)



• x HCl

RN 321915-83-7 HCAPLUS

CN 1,16-Hexadecanediamine, N,N'-bis(4-chloropentyl)-N,N'-dimethyl-,
hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 321915-84-8 HCAPLUS

CN Benzenecarbothioic acid, 4-(4-morpholinylmethyl)-, S,S'-(1,12-dodecanediyl)bis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 321915-62-2
CMF C50 H74 N4 08 S2


PAGE 1-A



PAGE 1-B



CM 2

CRN 144-62-7
CMF C2 H2 O4


RN 321915-85-9 HCPLUS

CN Benzenecarbothioic acid, 4-(4-morpholinylmethyl)-, S,S'-[1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-1-ethenediyl]]] ester, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 321915-62-2
CMF C50 H74 N4 O8 S2

PAGE 1-A




PAGE 1-B



CM 2


CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 321915-92-8 HCPLUS

CN Formamide, N,N'-1,12-dodecanediylbis[N-[2-[[2-(diethylamino)ethyl]dithio]-4-methoxy-1-methyl-1-butenyl]- (9CI) (CA INDEX NAME)



RN 321915-93-9 HCPLUS

CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-(benzoyloxy)-1-methyl-2-(propyldithio)-1-butenyl]- (9CI) (CA INDEX NAME)




IT 321915-86-0P 321915-89-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of neutral prodrugs of **bisquaternaryammonium parasiticides**)


RN 321915-86-0 HCPLUS

CN Thiazole, 5,5'-[1,6-hexanediylbis(oxy-2,1-ethanediyl)]bis[4-methyl- (9CI) (CA INDEX NAME)



RN 321915-89-3 HCPLUS

CN 4-Thiazoleacetic acid, 5,5'-(1,12-dodecanediyl)bis-, diethyl ester (9CI)
(CA INDEX NAME)



=>
=>

=> d 151 bib abs tot

L51 ANSWER 1 OF 6 HCPLUS COPYRIGHT 2003 ACS
 AN 2002:426419 HCPLUS
 DN 138:32620
 TI New drugs against **malaria** with special reference to effectors of **plasmodial** phospholipid metabolism
 AU Vial, Henri J.; Vidal-Sailhant, Valerie; Ancelin, Marie L.; Herbute, Serge; Martin, Dominique; Baunaure, F.; Calas, Michele
 CS UMR 5539 CNRS, Montpellier, 34095, Fr.
 SO Multi-Drug Resistance in Emerging and Re-Emerging Diseases, [Joint Symposium on Multiple Drug Resistance and Emerging Diseases], New Delhi, India, Feb. 28-Mar. 4, 1999 (2000), Meeting Date 1999, 175-189. Editor(s): Mahajan, R. C.; Therwath, Amu. Publisher: Indian National Science Academy, New Delhi, India.
 CODEN: 69CQYH; ISBN: 81-7319-346-0
 DT Conference; General Review
 LA English
 AB A review. The increasing multidrug resistance of **malarial parasites** to conventional **antimalarial** agents makes very acute the need for novel drugs, since, today, none of them can offer protection against **malaria** in all regions of the world. Drug development efforts generally aim for compds. that work through new, independent mechanisms of action and that are structurally unrelated to existing **antimalarial** agents. From this perspective, thorough biol. and biochem. studies of the **parasite** could lead to the discovery of a specific target that could be used in the design of original compds. capable of exterminating the **parasite** without injuring the host. Phospholipid biosynthesis in **Plasmodium** is of crucial importance considering the high degree of membrane biogenesis. Phospholipid metab. developed by **Plasmodium** during its intraerythrocytic cycle is essential and constitutes a novel pharmacol. target. The most promising interference is the blockade of the choline transporter protein, which provides **Plasmodium** with a precursor for the synthesis of phosphatidylcholine, the major phospholipid of infected erythrocytes. The 1st 2 generations of active lead compds. consisted of **quaternary** ammonium salts and amidine compds. The most prominent characteristics of these new mols. are: potent in vitro **antimalarial** activity against resistant *P. falciparum* strains and isolates, similar in vitro and in vivo activity against *P.*

vivax, absence of in vitro resistance induction under long-term drug pressure, in vivo activity in various murine species and *P. falciparum*-infected Aotus monkeys even at very high parasitemia, lack of recurrence, and absence of genotoxicity. Although tolerance was improved with the 2nd generation of compds., their intestinal absorption remained low. An original strategy has been initiated to design neutral prodrugs which require biotransformation once in the serum compartment (i.e., after passing through the intestinal barrier) to confer **antimalarial** activity. These prodrugs showed the same high in-vitro **antimalarial** activity (nM), tolerance (i.p. LD50 increased by 100-250-fold compared to cationic drugs) and high relative absorption (improved by 10-15-fold compared to cationic drugs). The **antimalarial** activity of these compds. is very satisfactory; all these considerations mean that the approach is now quite realistic. Overall, this pharmacol. approach is novel and should allow the design of candidates for initiating preclin. studies.

RE.CNT. 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:60210 HCAPLUS
DN 132:231503
TI **Antimalarial Activity of Compounds Interfering with Plasmodium falciparum Phospholipid Metabolism: Comparison between Mono- and Bisquaternary Ammonium Salts**
AU Calas, Michele; Ancelin, Marie L.; Cordina, Gerard; Portefaix, Philippe; Piquet, Gilles; Vidal-Sailhan, Valerie; Vial, Henri
CS Laboratoire des Aminoacides Peptides et Proteines, CNRS UMR 5810
Universite de Montpellier II, Montpellier, 34095, Fr.
SO Journal of Medicinal Chemistry (2000), 43(3), 505-516
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB On the basis of a previous structure-activity relationship study, we identified some essential parameters, e.g. electronegativity and lipophilicity, required for polar head analogs to inhibit *Plasmodium falciparum* phospholipid metab., leading to parasite death. To improve the in vitro **antimalarial** activity, 36 cationic choline analogs consisting of mono-, bis-, and **triquaternary** ammonium salts with distinct substituents of increasing lipophilicity were synthesized. For **monoquaternary** ammonium salts, an increase in the lipophilicity around nitrogen was beneficial for **antimalarial** activity: IC50 decreased by 1 order of magnitude from tri-Me to tri-Pr substituents. Irresp. of the polar head substitution (Me, Et, hydroxyethyl, pyrrolidinium), increasing the alkyl chain length from 6 to 12 methylene groups always led to increased activity. The highest activity was obtained for the N,N,N-tripropyl-N-dodecyl substitution of nitrogen (IC50 33 nM). Beyond 12 methylene groups, the **antimalarial** activities of the compds. decreased slightly. The structural requirements for **bisquaternary** ammonium salts in **antimalarial** activity were very similar to those of **monoquaternary** ammonium salts, i.e. polar head steric hindrance and lipophilicity around nitrogen (Me, hydroxyethyl, Et, pyrrolidinium, etc.). In contrast, with **bisquaternary** ammonium salts, increasing the lipophilicity of the alkyl chain between the two nitrogen atoms (from 5 to 21 methylene groups) constantly and dramatically increased the activity. Most of these duplicated mols. had activity around 1 nM, and the most lipophilic compd. synthesized exhibited an IC50 as low as 3 pM (21 methylene groups). Globally, this oriented synthesis produced 28 compds. out of 36 with an IC50 lower than 1 .mu.M, and 9 of them had an IC50 in the nanomolar range, with 1 compd. in the picomolar

range. This indicates that developing a pharmacol. model for antimalarial compds. through choline analogs is a promising strategy.

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 3 OF 6 HCPLUS COPYRIGHT 2003 ACS
AN 1998:105729 HCPLUS
DN 128:238968
TI **Antimalarial activity of 77 phospholipid polar head analogs: close correlation between inhibition of phospholipid metabolism and in vitro *Plasmodium falciparum* growth**
AU **Ancelin, Marie L.; Calas, Michele; Bompard, Jacques; Cordina, Gerard; Martin, Dominique; Bari, Mohammed Ben; Jei, Taib; Druilhe, Pierre; Vial, Henri J.**
CS CNRS UMR 5539, Department of Biologie-Sante, Montpellier, 34095, Fr.
SO Blood (1998), 91(4), 1426-1437
CODEN: BLOOAW; ISSN: 0006-4971
PB W. B. Saunders Co.
DT Journal
LA English
AB Seventy-seven potential analogs of phospholipid polar heads, choline and ethanolamine, were evaluated in vitro as inhibitors of **Plasmodium falciparum** growth. Their IC50 ranged from 10-3 to 10-7 mol/L. Ten compds. showed similar **antimalarial** activity when tested against three different **parasite** strains (2 chloroquine-sensitive strains and 1 chloroquine-resistant strain). Compds. showing marked **antimalarial** activity were assayed for their effects on phospholipid metab. The most active compds. (IC50 of 1 to 0.03 .mu.mol/L) were inhibitors of de novo phosphatidylcholine (PC) biosynthesis from choline. For a series of 50 compds., there was a close correlation between impairment of phospholipid biosynthesis and inhibition of in vitro **malaria parasite** growth. High choline concns. caused a marked specific shift in the curves for PC biosynthesis inhibition. Concns. inhibiting 50% PC metab. from choline were in close agreement with the Ki of these compds. for the choline transporter in **Plasmodium knowlesi**-infected erythrocytes. By contrast, measurement of the effects of 12 of these compds. on rapidly dividing lymphoblastoid cells showed a total absence of correlation between **parasite** growth inhibition and human lymphoblastoid cell growth inhibition. Specific **antimalarial** effects of choline or ethanolamine analogs are thus likely mediated by their alteration of phospholipid metab. This indicates that de novo PC biosynthesis from choline is a very realistic target for new **malaria** chemotherapy, even against pharmacoresistant strains.

L51 ANSWER 4 OF 6 HCPLUS COPYRIGHT 2003 ACS
AN 1998:98316 HCPLUS
DN 128:127745
TI Preparation of .alpha.,.omega.-bis(**quaternary ammonium**)alkane salt **antimalarial** and **antibabesiosis** agents
IN **Vial, Henri; Calas, Michele; Ancelin, Marie-Laure; Giral, Louis**
PA Virbac S.A., Fr.; Vial, Henri; Calas, Michele; Ancelin, Marie-Laure; Giral, Louis
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | WO 9804252 | A1 | 19980205 | WO 1997-FR1336 | 19970717 |

W: BR, CA, CN, JP, KR, US
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 FR 2751967 A1 19980206 FR 1996-9678 19960731
 FR 2751967 B1 19981009
 EP 917465 A1 19990526 EP 1997-934589 19970717
 EP 917465 B1 20021120
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 BR 9710629 A 19990817 BR 1997-10629 19970717
 CN 1232388 A 19991020 CN 1997-197753 19970717
 JP 2000515877 T2 20001128 JP 1998-508541 19970717
 AT 227984 E 20021215 AT 1997-934589 19970717
 US 6096788 A 20000801 US 1999-240627 19990201
 KR 2000029690 A 20000525 KR 1999-700769 19990929
 PRAI FR 1996-9678 A 19960731
 WO 1997-FR1336 W 19970717
 OS MARPAT 128:127745
 AB The title compds. R1(R2)(R3)N+XN+(R3)(R2)R1 [I; R1 = C1-20 hydrocarbyl;
 R2, R3 = (un)substituted C1-20 hydrocarbyl; X = (un)substituted C12-26
 dihydrocarbyl; counterion definitions not presented], having
 antimalarial and (veterinarian) **antibabesiasis** (e.g.,
 anti-piroplasmosis) activities, are prep'd. and a I-contg. formulation
 claimed. Thus, 1,21-dibromoheneicosane was reacted with MeNET₂, producing
 N,N'-dimethyl-N,N,N',N'-tetraethyl-1,21-heneicosanedi ammonium dibromide
 (m.p. 205), which demonstrated an in-vitro IC₅₀ assay of 0.000003 .mu.M
 against Babesia bovis and Babesia canis and a therapeutic index of 12.

L51 ANSWER 5 OF 6 HCPLUS COPYRIGHT 2003 ACS
 AN 1997:638456 HCPLUS
 DN 127:287699
 TI **Antimalarial Activity of Molecules Interfering with**
 Plasmodium falciparum Phospholipid Metabolism.
 Structure-Activity Relationship Analysis
 AU Calas, Michele; Cordina, Gerard; Bompart, Jacques; Bari, Mohamed
 Ben; Jei, Taieb; Ancelin, Marie L.; Vial, Henri
 CS Laboratoire des Aminoacides Peptides et Proteines, ESA CNRS 5075,
 Montpellier, Fr.
 SO Journal of Medicinal Chemistry (1997), 40(22), 3557-3566
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB A series of 80 compds., primary, secondary, and tertiary amines and
 quaternary ammonium and bisammonium salts, most of them
 synthesized as potential choline or ethanolamine analogs, were tested
 against the in vitro growth of **Plasmodium falciparum**,
 the human **malaria** parasite. They were active over the
 10-3-10-8 M concn. range. A structure-activity relationship study was
 carried out using autocorrelation vectors as structural descriptors, and
 multidimensional anal. Principal component anal., ascending hierarchical
 classification, and stepwise discriminant anal. showed that both the size
 and shape of the mol. were essential for **antimalarial** potency,
 making the lipophilicity and electronegativity distribution in the mol.
 space essential. Using the autocorrelogram describing the mol. shape and
 the electronegativity distribution on the mol. graph, 98% of the mols.
 were correctly classified either as poorly active or active with only
 three explanatory variables. The most active compds. were
 quaternary ammonium salts whose nitrogen atom had only one long
 lipophilic chain of 11 or 12 methylene groups or the bisammoniums whose
 polar heads were linked by linear alkyl chains of 10 to 12 carbon atoms.
 The hydroxyethyl group of choline was not very beneficial, whereas the
 charge and substitutions of nitrogen (aimed at increasing lipophilicity)
 were essential for optimal interactions. A crude topog. model of the

ligand (choline) binding site was thus drawn up.

L51 ANSWER 6 OF 6 HCPLUS COPYRIGHT 2003 ACS
 AN 1986:403415 HCPLUS
 DN 105:3415
 TI Quaternary ammonium compounds efficiently inhibit *Plasmodium falciparum* growth in vitro by impairment of choline transport
 AU Ancelin, Marie L.; Vial, Henri J.
 CS Cent. Natl. Rech. Sci., Inst. Natl. Sante Rech. Med., Montpellier, 34100, Fr.
 SO Antimicrobial Agents and Chemotherapy (1986), 29(5), 814-20
 CODEN: AMACQ; ISSN: 0066-4804
 DT Journal
 LA English
 AB Hemicholinium 3, decamethonium, and decyltrimethylammonium previously were demonstrated to be efficient inhibitors of *P. falciparum*, with 50% inhibitory concns. of 4 .times. 10⁻⁶, 10⁻⁶, and 7 .times. 10⁻⁷M, resp. Lengthening of the alkyl chain of decyltrimethylammonium by successive addns. of 2 C atoms up to hexadecyltrimethylammonium resulted in a very low 50% inhibitory concn. of 5 .times. 10⁻⁷ M for dodecyltrimethylammonium. Hemicholinium 3 and decamethonium exerted their antiplasmodial activity regardless of the developmental stage of the parasite, whereas decyltrimethylammonium was particularly lethal for the mature forms. After infected erythrocytes with radioactive choline were supplied, the detn. of the water-sol. choline-contg. compds. as well as the assay of choline kinase activity showed that the specific inhibition of phosphatidylcholine biosynthesis is related to the impairment of choline entry into erythrocytes. Thus, the impairment of the transport of choline, a natural polar head group of phospholipids, appears to be lethal for *P. falciparum* in vitro and could be a reasonable approach for a new malaria chemotherapy.

=> d his

(FILE 'HOME' ENTERED AT 16:22:06 ON 03 FEB 2003)
 SET COST OFF

FILE 'HCPLUS' ENTERED AT 16:22:26 ON 03 FEB 2003
 E FR99-9471/AP, PRN

L1 1 S E3, E4
 E WO2000-FR2122/AP, PRN
 L2 1 S E3, E4
 L3 1 S L1, L2
 SEL RN

FILE 'REGISTRY' ENTERED AT 16:23:09 ON 03 FEB 2003

L4 74 S E1-E74
 L5 4 S L4 AND CLH
 L6 2 S L5 NOT C6/ES
 L7 3 S L5 NOT C12H17NO2
 L8 1 S L7 NOT L6
 L9 70 S L4 NOT L5
 L10 25 S L9 AND 1 12 DODECANE?
 L11 10 S L10 AND C6/ES
 L12 8 S L11 NOT NCSC2/ES
 L13 6 S L12 AND 1/NC
 L14 4 S L11 NOT L13
 L15 2 S L14 NOT BR/ELS
 L16 15 S L10 NOT L11-L15
 L17 9 S L16 NOT NCSC2/ES
 L18 45 S L9 NOT L10-L17

L19 38 S L18 NOT NCSC2/ES
 L20 17 S L19 AND N/ELS
 L21 18 S L20 AND S/ELS
 L22 19 S L20 NOT L21
 L23 28 S L18 NOT L20-L22
 L24 7 S L23 AND NCSC2/ES
 L25 28 S L7, L8, L13, L15, L17, L21
 L26 4 S L24 AND NR>=2
 L27 39 S L4 NOT L24-L26
 L28 8 S L27 AND NCSC2/ES
 L29 31 S L27 NOT L28
 L30 15 S L24, L28

FILE 'HCAOLD' ENTERED AT 16:47:47 ON 03 FEB 2003
 L31 0 S L25

FILE 'HCAPLUS' ENTERED AT 16:47:52 ON 03 FEB 2003
 L32 1 S L25
 L33 1 S L26, L28
 L34 1 S L32, L33
 L35 1 S L34 AND L1-L3
 E VIAL H/AU
 L36 85 S E3-E8
 E CALAS M/AU
 L37 31 S E3-E5, E8
 E ANCELIN M/AU
 L38 41 S E3, E4, E6, E7
 E BOURGUIGNON J/AU
 L39 204 S E3, E5, E10, E12
 E VIDAL V/AU
 L40 34 S E3-E9, E14, E15
 E RUBI E/AU
 L41 13 S E3, E5
 L42 1 S L35 AND L36-L41
 L43 20 S L36-L41 AND (QUAT OR ?QUATERN?)
 E VIDAL SAILHANT V/AU
 L44 1 S E4
 L45 1 S E2
 E SAILHAN/AU
 L46 3 S E4, E5
 L47 20 S L36-L41, L44-L46 AND (QUAT OR ?QUATER?)
 L48 20 S L43, L47
 7 S L48 AND (?MALAR? OR ?PLASMOD? OR ?FALCIPAR? OR ?PARASIT? OR ?
 L49 1 S L35 AND L36-L49
 L50 6 S L49 NOT L50
 SEL RN

FILE 'REGISTRY' ENTERED AT 16:55:10 ON 03 FEB 2003
 L52 255 S E1-E255

FILE 'HCAPLUS' ENTERED AT 16:57:54 ON 03 FEB 2003

FILE 'HOME' ENTERED AT 16:20:32 ON 05 FEB 2003

=> file reg
COST IN U.S. DOLLARS
SINCE FILE
ENTRY
TOTAL
SESSION
0.21
0.21
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:20:43 ON 05 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 FEB 2003 HIGHEST RN 485752-98-5
DICTIONARY FILE UPDATES: 4 FEB 2003 HIGHEST RN 485752-98-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details.

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=>
Uploading 486.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> S 11
SAMPLE SEARCH INITIATED 16:21:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE
```

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

| | | |
|------------------------|--------|--------------|
| FULL FILE PROJECTIONS: | ONLINE | **COMPLETE** |
| | BATCH | **COMPLETE** |
| PROJECTED ITERATIONS: | 3 TO | 163 |
| PROJECTED ANSWERS: | 0 TO | 0 |

L2 0 SEA SSS SAM L1

=> s 11 ful
FULL SEARCH INITIATED 16:21:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 45 TO ITERATE


100.0% PROCESSED 45 ITERATIONS
SEARCH TIME: 00.00.01

19 ANSWERS

L3 19 SEA SSS FUL L1

=> d 13 15-19


L3 ANSWER 15 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 321915-54-2 REGISTRY
CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-methoxy-1-methyl-2-(propyldithio)-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C32 H60 N2 O4 S4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L3 ANSWER 16 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 321915-53-1 REGISTRY
CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-hydroxy-2-[(2-hydroxyethyl)dithio]-1-methyl-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H52 N2 O6 S4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L3 ANSWER 17 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 321915-52-0 REGISTRY
CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-hydroxy-1-methyl-2-[(phenylmethyl)dithio]-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C38 H56 N2 O4 S4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L3 ANSWER 18 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 321915-51-9 REGISTRY
CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-hydroxy-1-methyl-2-(propyldithio)-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C30 H56 N2 O4 S4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 19 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 321915-50-8 REGISTRY
CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-hydroxy-1-methyl-2-[(tetrahydro-2-furanyl)methyl]dithio]-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C34 H60 N2 O6 S4
SR CA
LC STN Files: CA, CAPLUS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d 13 1-14


L3 ANSWER 1 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 321915-93-9 REGISTRY
CN Formamide, N,N'-1,12-dodecanediylbis[N-[4-(benzoyloxy)-1-methyl-2-(propyldithio)-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C44 H64 N2 O6 S4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 2 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 321915-92-8 REGISTRY
CN Formamide, N,N'-1,12-dodecanediylbis[N-[2-[[2-(diethylamino)ethyl]dithio]-4-methoxy-1-methyl-1-butenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C38 H74 N4 O4 S4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 3 OF 19 REGISTRY COPYRIGHT 2003 ACS
RN 321915-85-9 REGISTRY
CN Benzenecarbothioic acid, 4-(4-morpholinylmethyl)-, S,S'-(1,12-dodecanediyl)bis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C50 H74 N4 O8 S2 . 2 C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS


CM 1

CRN 321915-62-2
CMF C50 H74 N4 O8 S2

PAGE 1-A




PAGE 1-B



CM 2

CRN 87-69-4
CMF C4 H6 06

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 4 OF 19 REGISTRY COPYRIGHT 2003 ACS

RN 321915-84-8 REGISTRY

CN Benzenecarbothioic acid, 4-(4-morpholinylmethyl)-, S,S'-(1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-1-ethenediyl]] ester, ethanedioate (1:2) (9CI) (CA INDEX NAME)

MF C50 H74 N4 O8 S2 . 2 C2 H2 O4


SR CA

LC STN Files: CA, CAPLUS


CM 1

CRN 321915-62-2
CMF C50 H74 N4 O8 S2

PAGE 1-A




PAGE 1-B



CM 2

CRN 144-62-7
CMF C2 H2 O4



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 5 OF 19 REGISTRY COPYRIGHT 2003 ACS


RN 321915-64-4 REGISTRY

CN Benzenecarbothioic acid, S,S'-(1,16-hexadecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-1-ethenediyl]] ester (9CI) (CA INDEX NAME)

MF C44 H64 N2 O6 S2

SR CA

LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 6 OF 19 REGISTRY COPYRIGHT 2003 ACS



RN 321915-63-3 REGISTRY

CN Benzoic acid, 4,4'-[5,18-diformyl-3,20-bis(2-methoxyethyl)-4,19-dimethyl-1,22-dioxo-2,21-dithia-5,18-diazadocosa-3,19-diene-1,22-diyl]bis-, dimethyl ester (9CI) (CA INDEX NAME)

MF C44 H60 N2 O10 S2

SR CA

LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 7 OF 19 REGISTRY COPYRIGHT 2003 ACS

RN 321915-62-2 REGISTRY

CN Benzenecarbothioic acid, 4-(4-morpholinylmethyl)-, S,S'-(1,12-dodecanediyl)bis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester (9CI) (CA INDEX NAME)


MF C50 H74 N4 O8 S2



CI COM

SR CA

LC STN Files: CA, CAPLUS

PAGE 1-A







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)



L3 ANSWER 8 OF 19 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-61-1 REGISTRY
 CN Benzenecarbothioic acid, 4-[(diethylamino)methyl]-, S,S'-(1,12-dodecanediyl)bis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester, dihydrochloride (9CI) (CA INDEX NAME)
 MF C50 H78 N4 O6 S2 . 2 Cl H
 SR CA
 LC STN Files: CA, CAPLUS



●2 HCl

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 9 OF 19 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-60-0 REGISTRY
 CN Benzenecarbothioic acid, 4-[(2-(4-morpholinyl)ethoxy]-, S,S'-(1,12-dodecanediyl)bis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester (9CI) (CA INDEX NAME)
 MF C52 H78 N4 O10 S2
 SR CA
 LC STN Files: CA, CAPLUS





— CH₂—OMe

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L3 ANSWER 10 OF 19 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-59-7 REGISTRY
 CN Benzenecarbothioic acid, 4-methoxy-, S,S'-[1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]]] ester (9CI) (CA INDEX NAME)
 MF C42 H60 N2 O8 S2
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L3 ANSWER 11 OF 19 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-58-6 REGISTRY
 CN Benzenecarbothioic acid, S,S'-[1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]]] ester (9CI) (CA INDEX NAME)
 MF C40 H56 N2 O6 S2
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L3 ANSWER 12 OF 19 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-57-5 REGISTRY
 CN Propanethioic acid, 2,2-dimethyl-, S,S'-(1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester (9CI) (CA INDEX NAME)
 MF C36 H64 N2 O6 S2
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L3 ANSWER 13 OF 19 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-56-4 REGISTRY
 CN Ethanethioic acid, S,S'-(1,12-dodecanediylbis[(formylimino)[1-(2-methoxyethyl)-2-methyl-2,1-ethenediyl]] ester (9CI) (CA INDEX NAME)
 MF C30 H52 N2 O6 S2
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 14 OF 19 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-55-3 REGISTRY
 CN Formamide, N,N'-1,12-dodecanediylbis[N-[1-methyl-2-(propyldithio)ethenyl]- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C26 H48 N2 O2 S4
 SR CA
 LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> file caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE
 ENTRY
 180.47

TOTAL
 SESSION
 180.68

FILE 'CAPLUS' ENTERED AT 16:21:51 ON 05 FEB 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Feb 2003 VOL 138 ISS 6
 FILE LAST UPDATED: 4 Feb 2003 (20030204/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
 L4 1 L3

=> d

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:63952 CAPLUS
 DN 134:131521
 TI Preparation of neutral prodrugs of bisquaternaryammonium parasiticides
 IN Vial, Henri; Calas, Michele; Ancelin, Marie-Laure; Bourguignon,
 Jean-Jacques; Vidal, Valerie; Rubi, Eric
 PA Centre National de la Recherche Scientifique (C.N.R.S.), Fr.
 SO PCT Int. Appl., 85 pp.
 CODEN: PIXXD2

DT Patent
 LA French

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2001005742 | A1 | 20010125 | WO 2000-FR2122 | 20000721 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |

FR 2796642 A1 20010126 FR 1999-9471 19990721
FR 2796642 B1 20011019
EP 1196371 A1 20020417 EP 2000-958598 20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
BR 2000012601 A 20020521 BR 2000-12601 20000721
PRAI FR 1999-9471 A 19990721
WO 2000-FR2122 W 20000721
OS MARPAT 134:131521

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 1.43 182.11

FILE 'CAOLD' ENTERED AT 16:22:26 ON 05 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 13
L5 0 L3

FILE 'HOME' ENTERED AT 16:27:26 ON 05 FEB 2003

FILE 'REGISTRY' ENTERED AT 16:27:36 ON 05 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 FEB 2003 HIGHEST RN 485752-98-5
DICTIONARY FILE UPDATES: 4 FEB 2003 HIGHEST RN 485752-98-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See **HELP CROSSOVER** for details.


Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details.

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 486.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STP



Structure attributes must be viewed using STN Express query preparation.

=> S 11
SAMPLE SEARCH INITIATED 16:27:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 143 TO ITERATE


100.0% PROCESSED 143 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
PROJ. ITNS: 2143 TO 3577
PROJ. ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> d 12 5

L2 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 47358-00-9 REGISTRY
CN Benzothiazolium, 3,3'-(1,6-hexanediy1)bis- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H22 N2 S2
CI COM



=> FIL STNGUIDE
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE ENTRY | TOTAL SESSION |
|---------------------|------------------|
| 2.88 | 3.09 |

FILE 'STNGUIDE' ENTERED AT 16:29:10 ON 05 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 31, 2003 (20030131/UP).

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE ENTRY | TOTAL SESSION |
|---------------------|------------------|
| 0.06 | 3.15 |

FILE 'REGISTRY' ENTERED AT 16:29:50 ON 05 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 FEB 2003 HIGHEST RN 485752-98-5
DICTIONARY FILE UPDATES: 4 FEB 2003 HIGHEST RN 485752-98-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 486.str

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 13
SAMPLE SEARCH INITIATED 16:30:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE


100.0% PROCESSED 9 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 1 TO 80

L4 1 SEA SSS SAM L3

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 321915-73-5 REGISTRY
CN Thiazolium, 3,3'-(1,12-dodecanediyl)bis[5-(2-methoxyethyl)-4-methyl-,
dibromide (9CI) (CA INDEX NAME)
MF C26 H46 N2 O2 S2 . 2 Br
SR CA
LC STN Files: CA, CAPLUS



2 Br⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 13 ful
 FULL SEARCH INITIATED 16:30:29 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 266 TO ITERATE


100.0% PROCESSED 266 ITERATIONS
 SEARCH TIME: 00.00.01

22 ANSWERS

L5 22 SEA SSS FUL L3


=> d 15 1-22

L5 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 477526-11-7 REGISTRY
 CN INDEX NAME NOT YET ASSIGNED
 MF C26 H32 N4 S2 . 2 Br
 SR Chemical Library



2 Br⁻


L5 ANSWER 2 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-75-7 REGISTRY
 CN Thiazolium, 3,3'-(1,16-hexadecanediyl)bis[5-(2-methoxyethyl)-4-methyl-, diiodide (9CI) (CA INDEX NAME)
 MF C30 H54 N2 O2 S2 . 2 I
 SR CA
 LC STN Files: CA, CAPLUS



2 I⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 3 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-74-6 REGISTRY
 CN Thiazolium, 3,3'-(1,12-dodecanediyl)bis[4-methyl-, diiodide (9CI) (CA INDEX NAME)
 MF C20 H34 N2 S2 . 2 I
 SR CA
 LC STN Files: CA, CAPLUS



2 I⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 4 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-73-5 REGISTRY
 CN Thiazolium, 3,3'-(1,12-dodecanediyl)bis[5-(2-methoxyethyl)-4-methyl-, dibromide (9CI) (CA INDEX NAME)
 MF C26 H46 N2 O2 S2 . 2 Br
 SR CA
 LC STN Files: CA, CAPLUS



2 Br⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 5 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 321915-72-4 REGISTRY
 CN Thiazolium, 3,3'-(1,12-dodecanediyl)bis[5-(2-hydroxyethyl)-4-methyl-, dibromide (9CI) (CA INDEX NAME)
 MF C24 H42 N2 O2 S2 . 2 Br
 SR CA
 LC STN Files: CA, CAPLUS



2 Br⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 6 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 146891-88-5 REGISTRY
 CN Thiazolium, 3,3'-(1,8-octanediyyl)bis[4,5-dimethyl-, dibromide (9CI) (CA INDEX NAME)
 MF C18 H30 N2 S2 . 2 Br
 SR CA
 LC STN Files: CA, CAPLUS



2 Br⁻

2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 7 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 146891-87-4 REGISTRY
 CN Thiazolium, 3,3'-(1,7-heptanediy1)bis[4,5-dimethyl-, dibromide (9CI) (CA
 INDEX NAME)
 MF C17 H28 N2 S2 . 2 Br
 SR CA
 LC STN Files: CA, CAPLUS



2 Br⁻

2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 8 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 146891-86-3 REGISTRY
 CN Thiazolium, 3,3'-(1,6-hexanediy1)bis[4,5-dimethyl-, dibromide (9CI) (CA
 INDEX NAME)
 MF C16 H26 N2 S2 . 2 Br
 SR CA
 LC STN Files: CA, CAPLUS



2 Br⁻

3 REFERENCES IN FILE CA (1962 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 9 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 146891-85-2 REGISTRY
 CN Thiazolium, 3,3'-(1,5-pentanediy1)bis[4,5-dimethyl-, dibromide (9CI) (CA INDEX NAME)
 MF C15 H24 N2 S2 . 2 Br
 SR CA
 LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)



2 Br⁻

2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 10 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 146891-84-1 REGISTRY
 CN Thiazolium, 3,3'-(1,4-butanediyl)bis[4,5-dimethyl-, dibromide (9CI) (CA INDEX NAME)
 MF C14 H22 N2 S2 . 2 Br
 SR CA
 LC STN Files: CA, CAPLUS



2 Br⁻

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 11 OF 22 REGISTRY COPYRIGHT 2003 ACS
RN 146891-83-0 REGISTRY
CN Thiazolium, 3,3'-(1,3-propanediyl)bis[4,5-dimethyl-, dibromide (9CI) (CA INDEX NAME)
MF C13 H20 N2 S2 . 2 Br
SR CA
LC STN Files: CA, CAPLUS



2 Br⁻

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 12 OF 22 REGISTRY COPYRIGHT 2003 ACS
RN 105420-27-7 REGISTRY
CN Thiazolium, 3,3'-(1,8-octanediyyl)bis[4-methyl-, dibromide (9CI) (CA INDEX NAME)
MF C16 H26 N2 S2 . 2 Br
SR CA
LC STN Files: CA, CAPLUS



2 Br⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 13 OF 22 REGISTRY COPYRIGHT 2003 ACS
RN 105420-26-6 REGISTRY
CN Thiazolium, 3,3'-(1,6-hexanediy)bis[4-methyl-, dibromide (9CI) (CA INDEX
NAME)
MF C14 H22 N2 S2 . 2 Br
SR CA
LC STN Files: CA, CAPLUS



2 Br⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 14 OF 22 REGISTRY COPYRIGHT 2003 ACS
RN 105420-25-5 REGISTRY
CN Thiazolium, 3,3'-(1,5-pentanediy)bis[4-methyl-, dibromide (9CI) (CA
INDEX NAME)
MF C13 H20 N2 S2 . 2 Br
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



●2 Br⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 15 OF 22 REGISTRY COPYRIGHT 2003 ACS
RN 105420-24-4 REGISTRY
CN Thiazolium, 3,3'-(1,3-propanediyl)bis[4-methyl-, dibromide (9CI) (CA INDEX NAME)
MF C11 H16 N2 S2 . 2 Br
SR CA
LC STN Files: CA, CAPLUS, CASREACT



2 Br⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 16 OF 22 REGISTRY COPYRIGHT 2003 ACS
RN 97745-74-9 REGISTRY
CN Thiazolium, 3,3'-(1,4-butanediyl)bis[4-methyl-, dibromide (9CI) (CA INDEX NAME)
MF C12 H18 N2 S2 . 2 Br
SR CA
LC STN Files: CA, CAPLUS, CASREACT



●2 Br⁻


3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 17 OF 22 REGISTRY COPYRIGHT 2003 ACS
RN 87051-17-0 REGISTRY
CN Thiazolium, 3,3'-(1,6-hexanediyi)bis[4-methyl-, dichloride (9CI) (CA INDEX NAME)
MF C14 H22 N2 S2 . 2 Cl



●2 Cl⁻

L5 ANSWER 18 OF 22 REGISTRY COPYRIGHT 2003 ACS
RN 76800-93-6 REGISTRY
CN Thiazolium, 3,3'-(1,3-propanediyl)bis[5-(2-chloroethyl)-4-methyl-, diiodide (9CI) (CA INDEX NAME)
MF C15 H22 Cl2 N2 S2 . 2 I
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



2 I⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 19 OF 22 REGISTRY COPYRIGHT 2003 ACS

RN 54642-19-2 REGISTRY


CN Thiazolium, 3,3'-(1,5-pentanediyi)bis[2,4-dimethyl-, dibromide (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,3'-Pentamethylenebis(2,4-dimethylthiazolium bromide)

MF C15 H24 N2 S2 . 2 Br

LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)



2 Br⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L5 ANSWER 20 OF 22 REGISTRY COPYRIGHT 2003 ACS

RN 54642-18-1 REGISTRY

CN Thiazolium, 3,3'-(1,4-butanediyl)bis[2,4-dimethyl-, diiodide (9CI) (CA INDEX NAME)

MF C14 H22 N2 S2 . 2 I

LC STN Files: BEILSTEIN*, CA, CAPLUS
 (*File contains numerically searchable property data)




2 I⁻

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 21 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 54642-17-0 REGISTRY
 CN Thiazolium, 3,3'-(1,3-propanediyl)bis[2,4-dimethyl-, diperchlorate (9CI)
 (CA INDEX NAME)
 OTHER NAMES:
 CN 3-3'-Trimethylenebis (2,4-dimethylthiazolium perchlorate
 MF C13 H20 N2 S2 . 2 Cl O4
 LC STN Files: CA, CAPLUS


CM 1

CRN 54642-16-9
 CMF C13 H20 N2 S2



CM 2


CRN 14797-73-0
 CMF Cl O4



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L5 ANSWER 22 OF 22 REGISTRY COPYRIGHT 2003 ACS
 RN 54642-16-9 REGISTRY
 CN Thiazolium, 3,3'-(1,3-propanediyl)bis[2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C13 H20 N2 S2

CI COM



=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE ENTRY | TOTAL SESSION |
|---------------------|------------------|
| 187.19 | 190.34 |

FILE 'CAPLUS' ENTERED AT 16:30:59 ON 05 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Feb 2003 VOL 138 ISS 6
FILE LAST UPDATED: 4 Feb 2003 (20030204/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15
L6 9 L5

=> d 16 1-9

L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 2001:63952 CAPLUS
DN 134:131521
TI Preparation of neutral prodrugs of bisquaternaryammonium parasiticides
IN Vial, Henri; Calas, Michele; Ancelin, Marie-Laure; Bourguignon, Jean-Jacques; Vidal, Valerie; Rubi, Eric
PA Centre National de la Recherche Scientifique (C.N.R.S.), Fr.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2001005742 A1 20010125 WO 2000-FR2122 20000721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 FR 2796642 A1 20010126 FR 1999-9471 19990721
 FR 2796642 B1 20011019
 EP 1196371 A1 20020417 EP 2000-958598 20000721
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 BR 2000012601 A 20020521 BR 2000-12601 20000721
 PRAI FR 1999-9471 A 19990721
 WO 2000-FR2122 W 20000721
 OS MARPAT 134:131521
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:786678 CAPLUS
 DN 123:313245
 TI A kinetic study by NMR of the benzoin condensation catalyzed by thiazolium salts in mild basic conditions: a second order process in both aldehyde and pre-catalyst
 AU Lopez-Calaborra, Francisco; Rubires, Raimon
 CS Department Quimica Organica, Universitat Barcelona, Barcelona, E-08028, Spain
 SO Tetrahedron (1995), 51(35), 9713-28
 CODEN: TETRAB; ISSN: 0040-4020
 PB Elsevier
 DT Journal
 LA English

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:36290 CAPLUS
 DN 122:9235
 TI Use of 3,3'-polymethylene-bridged thiazolium salts plus bases as catalysts of the benzoin condensation and its mechanistic implications: proposal of a new mechanism in aprotic conditions
 AU Lopez-Celaborra, Francisco; Castells, Josep; Domingo, Laura; Marti, Josep; Bofill, Josep M.
 CS Dep. Quimica Organica, Univ. Barcelona, Barcelona, 08028, Spain
 SO Heterocycles (1994), 37(3), 1579-97
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
 AN 1993:191094 CAPLUS
 DN 118:191094
 TI New evidence supporting bis(thiazolin-2-ylidene)s as the actual catalytic species in the benzoin condensation
 AU Castells, Josep; Domingo, Laura; Lopez-Calaborra, Francisco; Marti, Josep
 CS Dep. Quim. Org., Univ. Barcelona, Barcelona, 08028, Spain
 SO Tetrahedron Letters (1993), 34(3), 517-20
 CODEN: TELEAY; ISSN: 0040-4039
 DT Journal
 LA English

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS
 AN 1987:84464 CAPLUS
 DN 106:84464
 TI 3,3'-Tetramethylene-bridged 4-methylthiazolium salt as an organic redox catalyst. The partial reduction of nitrosobenzene with benzaldehyde to azoxybenzene
 AU Inoue, Hiroo; Tamura, Shigeo
 CS Coll. Eng., Univ. Osaka Prefect., Sakai, 591, Japan
 SO Chemistry Express (1986), 1(5), 291-4
 CODEN: CHEXEU; ISSN: 0911-9566
 DT Journal

LA English

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

AN 1986:625923 CAPLUS

DN 105:225923

TI Catalytic function of a 3,3'-tetramethylene-bridged 4-methylthiazolium salt in the reductive cleavage of the sulfur-sulfur bond of disulfides with o-methylbenzaldehyde and bases

AU Inoue, Hiroo; Tamura, Shigeo

CS Dep. Appl. Chem., Univ. Osaka Prefect., Osaka, 591, Japan

SO Journal of the Chemical Society, Chemical Communications (1986), (11), 858-9

CODEN: JCCCAT; ISSN: 0022-4936

DT Journal

LA English

OS CASREACT 105:225923

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS

AN 1985:487566 CAPLUS

DN 103:87566

TI Novel catalytic system consisting of a 3,3'-tetramethylene-bridged 4-methylthiazolium salt leading to the partial reduction of nitrobenzene with benzaldehyde to a nitrone

AU Inoue, Hiroo; Tamura, Shigeo

CS Dep. Appl. Chem., Univ. Osaka Prefect., Osaka, 591, Japan

SO Journal of the Chemical Society, Chemical Communications (1985), (3), 141-2

CODEN: JCCCAT; ISSN: 0022-4936

DT Journal

LA English

OS CASREACT 103:87566

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS

AN 1981:103319 CAPLUS

DN 94:103319

TI A novel base-induced ring expansion of quaternized heterocycles

AU Federsel, Hans Juergen; Bergman, Jan

CS Dep. Org. Chem., R. Inst. Technol., Stockholm, S-100 44, Swed.

SO Tetrahedron Letters (1980), 21(25), 2429-32

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS

AN 1975:141589 CAPLUS

DN 82:141589

TI Biscyanines with nonconjugated chromophores from 2,4-dimethylthiazole and lepidine derivatives

AU Mushkalo, I. L.; Shedov, I. F.

CS Inst. Org. Khim., Kiev, USSR

SO Khimiya Geterotsiklichesikh Soedinenii (1974), (11), 1489-92

CODEN: KGSSAQ; ISSN: 0132-6244

DT Journal

LA Russian